Evidence map›Paper›PMID 42173190›Full record

ArticleAmerican journal of ophthalmology2026

Ocular Hypertension Treatment Study: Effect of Time After Incident Glaucoma on OCT Optic Nerve Head and Macula Measurements.

Evan Walker, Christopher Bowd, Sonia Jain, Julia Huecker, Keri A Dirkes, Suzanne Vega, Maria Hunsicker, Mae O Gordon, Michael A Kass, Robert N Weinreb and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Evan WalkerFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Christopher BowdFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA; The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Division of Ophthalmology Informatics and Data Science (C.B., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Sonia JainHerbert Wertheim School of Public Health and Human Longevity Science, Biostatistics Research Center (S.J.), University of California San Diego, La Jolla, California, USA.
Julia HueckerData Science and Biostatistics, Institute for Informatics (J.H., M.O.G.), Washington University School of Medicine in St Louis, St Louis, Missouri, USA.
Keri A DirkesFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Suzanne VegaFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Maria HunsickerFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Mae O GordonData Science and Biostatistics, Institute for Informatics (J.H., M.O.G.), Washington University School of Medicine in St Louis, St Louis, Missouri, USA; Department of Ophthalmology and Visual Sciences (M.O.G., M.A.K.), Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Michael A KassDepartment of Ophthalmology and Visual Sciences (M.O.G., M.A.K.), Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Robert N WeinrebFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA; The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Division of Ophthalmology Informatics and Data Science (C.B., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA.
Linda M ZangwillFrom the The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center (E.W., C.B., K.A.D., S.V., M.H., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA; The Viterbi Family Department of Ophthalmology and Shiley Eye Institute, Division of Ophthalmology Informatics and Data Science (C.B., R.N.W., L.M.Z.), University of California San Diego, La Jolla, California, USA. Electronic address: lzangwill@ucsd.edu.

Funding

OCULAR HYPERTENSION TREATMENT STUDY (OHTS)U10EY009307 · NEI · WASHINGTON UNIVERSITY · PI KASS, MICHAEL A · 1992 to 2009
$14.8M
African Descent And Glaucoma Evaluation Study (ADAGES)U10EY014267 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2002 to 2010
$13.2M
OHTS DATA COORDINATIONU10EY009341 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 1992 to 2009
$12.3M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center GrantUG1EY025182 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 2015 to 2019
$4.9M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
Ocular Hypertension Treatment Study 20-Year Follow-up: Resource Center GrantUG1EY025183 · NEI · WASHINGTON UNIVERSITY · PI KASS, MICHAEL A · 2015 to 2019
$4.0M
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center GrantUG1EY025181 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 2015 to 2019
$3.4M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
Monitoring of Glaucoma Patients in Advanced DiseaseR01EY034148 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sasan Moghimi Araghi · 2022 to 2026
$2.5M
NEI NIH HHS P30 EY022589NEI NIH HHS R00 EY030942NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY022039NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058NEI NIH HHS R01 EY034146NEI NIH HHS R01 EY034148NEI NIH HHS R21 EY027945NEI NIH HHS R21 EY031125NEI NIH HHS U10 EY009307NEI NIH HHS U10 EY009341NEI NIH HHS U10 EY014267NEI NIH HHS UG1 EY025180NEI NIH HHS UG1 EY025181NEI NIH HHS UG1 EY025182NEI NIH HHS UG1 EY025183
6 · The paper itself

Abstract

purposeThe objectives of this report are to compare optical coherence tomography (OCT) based retinal nerve fiber layer (RNFL) and ganglion cell / inner plexiform layer (GCIPL) thickness in participants who developed primary open-angle glaucoma (POAG) in the Ocular Hypertension Treatment Study (OHTS) to RNFL and GCIPL thickness in those who did not develop POAG (ie, a parallel control group) and to elucidate the relationship between duration after reaching an OHTS POAG endpoint and RNFL and GCIPL thickness.

designClinical cohort study using OCT data.

methodsSix hundred and forty six OHTS participants who completed OHTS 3 visit OCT imaging were included. Cirrus and Spectralis parapapillary RNFL and GCIPL thickness measurements were compared between 450 eyes that developed POAG and 723 eyes in the control group that did not develop POAG.

resultsIn eyes that developed POAG compared to eyes that did not develop POAG, mean global RNFL thickness was between 11.1 and 12.7 µm thinner and mean global GCIPL was between 4.5 and 7.6 µm thinner using Spectralis and Cirrus OCT, respectively (all comparisons P < .001). The 10+ years after POAG diagnosis POAG eyes had ∼10% thinner mean global RNFL thickness and GCIPL thickness than eyes with shorter durations after POAG diagnosis.

conclusionsIn the OHTS, the ocular hypertensive eyes that developed POAG had significantly thinner RNFL and GCIPL measurements compared with the ocular hypertensive eyes that did not develop glaucoma. In addition, longer duration of POAG was associated with thinner RNFL/GCIPL independent of POAG treatment status and IOP level. These results characterize the magnitude of RNFL and GCIPL thinning associated with increasing POAG duration and reinforce the role of OCT as a key tool for monitoring glaucomatous structural change in eyes with OH.

Indexed as

Glaucoma, Open-AngleMacula LuteaNerve FibersOcular HypertensionOptic DiskRetinal Ganglion CellsTomography, Optical CoherenceAgedAntihypertensive AgentsFemaleHumansIntraocular PressureMaleMiddle AgedRandomized Controlled Trials as TopicTime FactorsAntihypertensive Agents

Identifiers

PMID42173190
PMCPMC13543928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.